Double hit lymphoma (DHL) is an aggressive type of B-cell lymphoma defined by two specific genetic mutations: rearrangements in both the MYC gene and the BCL2 or BCL6 gene. It accounts for roughly 5% to 7% of all diffuse large B-cell lymphomas (DLBCL), the most common type of non-Hodgkin lymphoma. Because two cancer-promoting genes are simultaneously switched on, this lymphoma grows faster and is harder to treat than typical DLBCL.
The Genetics Behind the Name
The “hits” in double hit lymphoma refer to chromosomal translocations, where segments of DNA break off and reattach in the wrong place. The first hit involves the MYC gene, which drives rapid cell growth. The second hit involves either BCL2, a gene that prevents damaged cells from dying, or BCL6, a gene that helps cancer cells evade the immune system. When both of these genetic switches are flipped at once, lymphoma cells multiply quickly and resist normal cell death signals.
The World Health Organization classifies this combination as “high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.” A related entity called triple hit lymphoma involves rearrangements in all three genes: MYC, BCL2, and BCL6.
Double Hit vs. Double Expressor Lymphoma
These two terms sound similar but describe different problems. Double hit lymphoma is a genetic diagnosis: the DNA itself is rearranged. Double expressor lymphoma (DEL) is a protein-level diagnosis: the cancer cells produce too much MYC and BCL2 protein, but the underlying chromosomes haven’t been rearranged. DEL is more common, showing up in 20% to 30% of DLBCL cases, and it also carries a worse prognosis than standard DLBCL. However, it is not classified as its own distinct disease in the way DHL is. The distinction matters because the two conditions may respond differently to treatment and to newer therapies like CAR T-cell therapy.
How It Presents
Double hit lymphoma tends to show up at an advanced stage with aggressive features. In one analysis from MD Anderson Cancer Center, 84% of patients already had stage III or IV disease at the time of diagnosis, and 65% were male. Elevated lactate dehydrogenase (LDH), a blood marker that signals rapid cell turnover, is a hallmark. One study found 92% of DHL patients had elevated LDH levels. The cancer also frequently spreads beyond the lymph nodes into other organs (extranodal disease), which was present in 93% of patients in the same analysis.
Common symptoms mirror those of other aggressive lymphomas: rapidly growing lumps in the neck, armpits, or groin, along with drenching night sweats, unexplained weight loss, and fatigue. Because DHL often involves organs outside the lymph nodes, some people first notice symptoms related to wherever the cancer has spread, such as bone pain, abdominal swelling, or neurological changes.
How It Is Diagnosed
A standard tissue biopsy can identify DLBCL under the microscope, but detecting the specific genetic rearrangements requires an additional test called fluorescence in situ hybridization, or FISH. This lab technique uses fluorescent probes that attach to specific gene locations, allowing pathologists to see whether MYC, BCL2, or BCL6 have been rearranged. Current guidelines recommend FISH testing on all newly diagnosed cases of DLBCL specifically to catch the subset that qualifies as double hit.
Before FISH, doctors often use immunohistochemistry (IHC) as a screening step. IHC stains the biopsy tissue to measure how much MYC and BCL2 protein the tumor cells are producing. If both proteins are overexpressed, that flags the case for FISH testing to determine whether the overexpression stems from actual genetic rearrangements. In one study of 272 aggressive B-cell lymphomas, about 22% showed co-expression of MYC and BCL2 proteins on IHC, but only a fraction of those turned out to have the chromosomal rearrangements that define true DHL.
Treatment Approaches
Standard chemotherapy for DLBCL is a regimen called R-CHOP, but DHL responds poorly to it. Five-year overall survival rates with R-CHOP alone range from just 22% to 27% for double hit patients. Because of these dismal numbers, many cancer centers use a more intensive regimen called DA-R-EPOCH, which delivers chemotherapy as a continuous infusion over several days and adjusts doses based on how the patient’s blood counts respond. Phase 2 data show higher five-year survival rates with this approach compared to historical R-CHOP results, though no large randomized trial has directly compared the two in DHL patients. A meta-analysis of 11 retrospective studies found that DA-R-EPOCH extended the time before the disease progressed, though the overall survival benefit was not statistically significant.
For patients who respond well to initial chemotherapy, some centers follow up with a stem cell transplant using the patient’s own cells (autologous transplant) to consolidate the response. One program at Oregon Health & Science University reported a two-year progression-free survival of 91% in DHL patients who received DA-R-EPOCH followed by a transplant. These results are encouraging, but they come from a small group of 16 patients, and larger European studies of transplant in high-risk DLBCL have not consistently confirmed the benefit. The approach is generally reserved for patients who are physically fit enough to tolerate the intensive recovery process.
When the Cancer Returns
If DHL relapses after initial treatment, options include CAR T-cell therapy, a treatment in which a patient’s own immune cells are genetically reprogrammed in a lab to recognize and attack lymphoma cells, then infused back into the body. A multicenter analysis found that DHL patients treated with CAR T-cell therapy had a median progression-free survival of 7.5 months, comparable to non-DHL patients at 6.2 months. Median overall survival was about 21 months for DHL patients. However, DHL patients who relapsed after CAR T-cell therapy had the worst subsequent survival, suggesting the cancer becomes increasingly treatment-resistant with each recurrence.
Prognosis and What Affects It
Double hit lymphoma carries a significantly worse prognosis than standard DLBCL, and long-term survivors are rare with conventional treatment. The specific gene partner matters: MYC/BCL2 double hits tend to behave more aggressively than MYC/BCL6 combinations, though both are serious. Stage at diagnosis, LDH level, and the patient’s overall fitness all factor into individual outlook.
With more intensive frontline regimens and consolidation strategies, outcomes are improving for a subset of patients. The shift toward routine FISH testing has also helped, since identifying DHL at diagnosis allows oncologists to skip standard R-CHOP and move directly to more aggressive treatment. Early, accurate genetic classification is one of the most important factors in giving DHL patients the best chance at a durable response.